Second medical use or indication claims
|
|
- Angelina Hunter
- 5 years ago
- Views:
Transcription
1 Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Bulgarian National Group Second medical use or indication claims Valentina NESHEVA Valentina NESHEVA Date: 16 May 2014 Questions I. Current law and practice Groups are invited to answer the following questions under their national laws. If those national and regional laws apply to a set of questions, please answer the questions separately for each set of laws. Please number your answers with the same numbers used for the corresponding questions. 1) Does your country permit patents covering any aspect of new uses of known pharmaceutical compounds (hereafter referred to as second medical use claims)? If yes, please answer Questions 2) to 7) inclusive before proceeding to the questions in Parts I and II. If no, please proceed directly to the questions in Parts II and III. 2) If the answer to Question 1) is yes, please answer the following sub questions. a) What is the basis for patent protection? There is no explicit legal basis in the Bulgarian Law on Patents and Registration of Utility Models (LPRUM) providing for the legal protection of a second medical use of known compounds. Art. 6 of LPRUM say: Any inventions in any technical field are patentable, provided they are novel, have inventive step and are industrially applicable. In addition Art. 11 (13) of the Regulation on Drafting, Filing and Examination of Patent Applications (RDFEPA) indirectly provides a legal basis for the protection of second medical use, foreseeing that: When the claim relates to the use of known substances or compositions in methods for treatment or diagnostics of humans or animals, it is drafted without dividing the claim in parts. b) What types of second medical use are patentable? See, for example, paragraphs 14) - 17) above/wgls. In view of the fact that the requirements for patentable invention are novelty, inventive step and industrial applicability, the problem with any type of second medical use will 1
2 be if the claimed second medical use has inventive step over the prior art and in particular in relation to the first medical use. Obviously the use for treating a different disease where the known compound or composition already has first medial use (whether protected and actively applied or not) may have inventive step and may be granted legal protection. However if a mere change of the dosage regime is questionable has an inventive step is very questionable and such a claim will rather not be granted legal protection. c) Are any types of second medical use impermissible subject matter? See, for example, paragraphs 14) - 17) above/wgls. In view of the fact that the Bulgarian patent law does not explicitly provide for the protection of a second medical use, it does not also differentiate between any special types of such a second medical use. d) What forms of second medical use claims are permissible? See, for example, paragraphs 26) - 33) above/wgls. There is no particular type of claim required by the Bulgarian Patent Office but claiming Method for treatment is not allowed because such methods are deemed to lack industrial applicability. In principle the practice of the BPO is harmonized with the practice of the EPO with the distinction that the Swiss type claim will be allowed by the BPO, while this type of claim is not permissible any more before the EPO. e) What forms of second medical use claims are not permissible? See, for example, paragraphs 26) - 33) above/wgls. Claim for method of treatment of human or animal is not permissible. All other types of wording of a claim for second medical use are permissible. f) Has any guidance been provided by courts or the national patent office in relation to the meaning, scope and/or effect of 'treatment', 'treating' or 'use to treat' integers in second medical use claims? See, for example, paragraphs 34) - 39) above WGLs. There is no guidance provided by the Bulgarian Patent Office or the courts regarding the meaning of treatment, treating or use to treat and no distinction is made between these terms. 3) If your country permits second medical use claims: a) Who may be liable for infringement of such claims? For example: i) the party marketing the drug with label instructions which describe the patented use; Yes ii) the physician prescribing the drug for such use; No iii) the pharmacist dispensing a drug for such purpose; Yes iv) the patient using the drug for such purpose? No The Bulgarian patent law provides for the right of the patent proprietor to use the patented invention, to forbid such a use by third parties and to dispose of the patent. The right to use includes the production, offering for sale, trade with the patented invention, including the import and use of the patented product and the implementation of the patented method. Therefore the third parties may not engage in such activities without the consent of the patent proprietor. In the above cases the party marketing a drug to be used for the patented use is clearly infringing the patent for a second medical use. The physician prescribing the drug cannot be held 2
3 responsible in view of the fact that he is not using the patented invention but carries out his profession for the benefit of the patient as his oath as a medical doctor obliges him. The pharmacists are infringing the patent with one specific exclusion provided by the law. The patient taking the drug to treat his medical condition or disease will not be held accountable for infringing the patent. In all cases of infringing activities it is necessary that the alleged infringer has acted intentionally. b) Are any parties exempt from infringement or liability for infringement of such claims. If so, what classes of party? Art. 20 of LPRUM provides for specific limitations of the exclusive right of the patent proprietor which are: 1. Use of the patented invention for non-commercial purposes relating to personal needs, if such use does not significantly hurt financially the patent proprietor; 2. Use of the patented invention for experimental purposes or for scientific research relating to the subject of invention; 3. One-time direct preparation of a drug in a pharmacy on grounds of a prescription by a medical doctor; c) Are such claims enforceable on the basis of direct or indirect infringement? Please provide details. The Bulgarian patent law does not distinguish between direct and indirect infringement. Claims for second medical use may be enforceable in all above mentioned cases of infringement. 4) If a drug is approved for more than one indication, one or more of which (but not all) falls within the claims of a patent, is it an infringement if a party makes, supplies or uses a generic version of the drug for any use? If the patent claims protect only the use of a known chemical compound or pharmaceutical composition, the production and marketing of this compound or preparation not for the patented use but for some other use is not infringing the patent. 5) If the answer to Question 4) is yes, please answer the following sub questions in that context. a) Is each of the acts of making, supplying and using a form of infringement? If not, please specify which (or any other) acts which constitute infringement. b) Is it necessary for a finding of infringement that the party making, supplying or using the generic version of the drug does so in connection with the infringing use? c) If yes to b), is it necessary that the party knows that their actions are in connection with the infringing use? d) If yes to c), what standard of knowledge is required? See, for example, paragraphs 38) and 47) above. 6) How do the courts determine infringement of a second medical use claim? What are the legal tests and evidentiary requirements? Bulgarian courts have very limited practice in patent cases and no specific tests or evidentiary requirements have been developed in this regard. 3
4 7) What relief is available for infringement of a second medical use claim: a) at a preliminary / interim / interlocutory level? There is no sufficient court practice to show if the court may allow preliminary injunction on grounds of a second medical use claim. Anyway if such a preliminary injunction is admitted, the court surely will require money bond to preserve the rights of the attacked party in case the patent proprietor fails to prove his claim for infringement of his patent before the court. b) by way of final relief? The patent proprietor may claim and receive any direct damages resulting from the infringing activities of the alleged infringer. Furthermore the court may order the infringer to discontinue the infringement if the patent proprietor so requests. 8) In respect of Question 7)a), can a preliminary / interim / interlocutory injunction be granted solely upon the statements provided in the product packaging or based on the writing of a prescription? If not, what is the basis for relief? There is no sufficient court practice to answer this question. 9) In respect of Question 7)b), what level of proof is required to obtain a final injunction? The patent proprietor is obliged to prove fully his allegations with any admissible evidentiary means documents, requesting court order to provide information that is in possession of third parties or the infringer, examination by experts appointed by the court like patent experts, financial or accounting experts; questioning of witnesses. 4
5 II. Policy considerations and proposals for improvements to your current law 10) If your country permits second medical use claims, please answer the following sub questions. a) What are the policy reasons behind permitting such claims? The Bulgarian legislation and the practice of the Bulgarian Patent Office are harmonized with the other European countries according to the obligations of Bulgaria as member state of EC. Although the Bulgarian patent law does not provide explicitly for the legal protection of second medical use claims, considerations relating to public health and preserving rights of patent proprietors resulted in admitting such claims to legal protection in Bulgaria, in accordance with the practice of EPO. Yes. b) Are such claims as are currently permissible in your country considered to strike the right balance between the interests of relevant stakeholders? No. c) Is it considered that such claims better serve the interests of some stakeholders and/or are detrimental to other stakeholders? d) If there is any empirical or anecdotal data available, please address the following. i) What is the prevalence of second medical use claims in your country? ii) What is the profile of patentees for second medical use claims in your country? 11) If your country does not permit second medical use claims, please answer the following sub questions. a) What are the policy reasons behind not permitting such claims? b) Would such claims serve the interests of relevant stakeholders? c) Would such claims be considered to better serve the interests of some stakeholders and/or be detrimental to other stakeholders? 12) To what extent does your country's law in relation to second medical use claims affect the pharmaceutical industry (originator and generic) in your country? III. Proposals for harmonisation The Groups are invited to put forward proposals for the adoption of harmonized laws in relation to second medical use claims. More specifically, the Groups are invited to answer the following questions without regard to their existing national laws. 13) Is it desirable to permit second medical use claims? Yes, it certainly is desirable to permit such claims in order to stimulate scientific research and to improve the public health. 5
6 14) Is harmonization of laws relating to second medical use claims desirable? Yes. 15) Please provide a standard that you consider to be best in each of the following areas relating to second medical use claims. 14) 17) a) Types of second medical use constituting permissible subject matter. See, for example, paragraphs 14) - 17) above/wgls. None. b) Types of any second medical use constituting impermissible subject matter. See, for example, paragraphs 14) - 17) above/wgls. 26) 33) None. c) Form of permissible claims. See, for example, paragraphs 26) - 33) above/wgls. d) Form of impermissible claims. See, for example, paragraphs 26) - 33) above/wgls. e) Who may be liable for infringement? The party financially benefitting from the infringement. Any use for personal needs should be excluded from infringement to preserve the right of any person to live and seek means to save his/her life or to get healthy. f) Any parties/institutions that should be exempted from infringement or liability for infringement. Patients and medical doctors if the latter do not benefit financially from the infringement. Pharmacists dispensing drugs according to a prescription by a medical doctor. g) Where a drug is approved for more than one indication, one or more of which (but not all) falls within the claims of a patent, the acts that should constitute patent infringement, and in particular, the standard of knowledge of the alleged infringer. Producing and marketing the drug with packaging on which is indicated the patented second medical use. h) Relief available upon a finding of infringement: i) at a preliminary / interim / interlocutory level; and ii) by way of permanent relief. The current situation in Bulgaria provides the necessary balance between preserving the rights of the patent proprietor and not admitting groundless claims or using patent rights unfairly to hurt competitors. i) In each case for h)i) and h)ii), the level of proof for the granting of such relief. 6
7 The patent proprietor attacking an alleged infringer has to initiate a lawsuit proving his case at least at first glance and furthermore a money bond should be placed on allowing a preliminary injunction in order to preserve the rights of the alleged infringer if the patent proprietor fails to prove his allegations. 7
Second medical use or indication claims
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Egyptian National Group Second medical use or indication claims Eman MOHEY, Gamal ABOU ALI Ahmed ABOU ALI Date: May
More informationSecond medical use or indication claims. [Please insert name last name in CAPITAL letters please]
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: New Zealand Second medical use or indication claims Michael BROWN, Partner Helen BELLCHAMBERS, Associate A J Park [Please
More informationSecond medical use or indication claims. Mr. Antonio Ray ORTIGUERA Angara Abello Concepcion Regala & Cruz Law Offices Philippines
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: PHILIPPINES Second medical use or indication claims Mr. Alex Ferdinand FIDER Mr. Antonio Ray ORTIGUERA Angara Abello
More informationSecond medical use or indication claims. Winnie Tham, Edmund Kok, Nicholas Ong
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: AIPPI SINGAPORE Second medical use or indication claims Winnie Tham, Edmund Kok, Nicholas Ong THAM, Winnie Date: 17
More informationSecond medical use or indication claims
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Canada Second medical use or indication claims Matthew ZISCHKA Santosh CHARI Carol HITCHMANN Roseanne CALDWELL Charles
More informationPatentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector
Patentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector 2012 LIDC Congress, Prague, 12 October 2012 Dr. Simon Holzer, Attorney-at-Law, Partner 3 October 2012 2 Introduction! Conflicting
More informationNo. According to the PTO s internal examination guidelines, second medical use claims are not patentable.
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Argentina Second medical use or indication claims Gastón RICHELET, Ricardo D. RICHELET Gastón RICHELET Date: May 19,
More informationSecond medical use or indication claims
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: AUSTRIA Second medical use or indication claims Marc KESCHMANN Marc KESCHMANN Date: May 12, 2014 Questions I. Current
More informationConstruction of second medical use claims. The Hon. Mr Justice Richard Arnold
Construction of second medical use claims The Hon. Mr Justice Richard Arnold The problem Claim 1 of European Patent (UK) No. 0 934 061 reads: Use of [pregabalin] or a pharmaceutically acceptable salt thereof
More informationWorking Guidelines Q238. Second medical use and other second indication claims
Working Guidelines by Thierry CALAME, Reporter General Sarah MATHESON and John OSHA, Deputy Reporters General Anne Marie VERSCHUR, Sara ULFSDOTTER and Kazuhiko YOSHIDA Assistants to the Reporter General
More informationNotwithstanding Article 29, any invention that is liable to injure public order, morality or public health shall not be patented (Article 32).
Japan Patent Office (JPO) Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 2 Section 3: Experimental use and/or scientific research... 3 Section 4: Preparation of medicines...
More informationIntellectual Property Department Hong Kong, China. Contents
Intellectual Property Department Hong Kong, China Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 3 Section 3: Experimental use and/or scientific research... 3 Section
More informationSecond Medical Use Patents in Europe: Are the UK and Germany Swapping Approaches?
WHITE PAPER January 2019 Second Medical Use Patents in Europe: Are the UK and Germany Swapping Approaches? The UK Supreme Court s ruling in Warner Lambert v Actavis resulted from deliberations over the
More informationSuzannah K. Sundby. canady + lortz LLP. David Read. Differences between US and EU Patent Laws that Could Cost You and Your Startup.
Differences between US and EU Patent Laws that Could Cost You and Your Startup Suzannah K. Sundby United States canady + lortz LLP Europe David Read UC Center for Accelerated Innovation October 26, 2015
More informationCA/PL 7/99 Orig.: German Munich, SUBJECT: Revision of the EPC: Articles 52(4) and 54(5) President of the European Patent Office
CA/PL 7/99 Orig.: German Munich, 2.3.1999 SUBJECT: Revision of the EPC: Articles 52(4) and 54(5) DRAWN UP BY: ADDRESSEES: President of the European Patent Office Committee on Patent Law (for opinion) SUMMARY
More informationHow patents work An introduction for law students
How patents work An introduction for law students 1 Learning goals The learning goals of this lecture are to understand: the different types of intellectual property rights available the role of the patent
More informationSwitzerland. Esther Baumgartner Christoph Berchtold Simon Holzer Kilian Schärli Meyerlustenberger Lachenal. 1. Small molecules
Esther Baumgartner Christoph Berchtold Simon Holzer Kilian Schärli Meyerlustenberger Lachenal 1. Small molecules 1.1 Product and process claims Classic drug development works with small, chemically manufactured
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
The answers to this questionnaire have been provided on behalf of: Country: Germany Office: Federal Ministry of Justice and for Consumer Protection / German Patent and Trademark Office Person to be contacted:
More informationSelection Inventions the Inventive Step Requirement, other Patentability Criteria and Scope of Protection
Question Q209 National Group: Title: Contributors: AIPPI Indonesia Selection Inventions the Inventive Step Requirement, other Patentability Criteria and Scope of Protection Arifia J. Fajra (discussed by
More informationFrequently Asked Questions. Trade/service marks: What is a trade/service mark?
Frequently Asked Questions Trade/service marks: What is a trade/service mark? Is a distinctive sign that serves to distinguish the goods and/or services of one enterprise from those of other enterprises.
More informationPatent Act, B.E (1979) As Amended until Patent Act (No.3), B.E (1999) Translation
Patent Act, B.E. 2522 (1979) As Amended until Patent Act (No.3), B.E. 2542 (1999) Translation BHUMIBOL ADULYADEJ, REX. Given on the 11th day of March, B.E. 2522; Being the 34th year of the present Reign
More information[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights
[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Office: EL SALVADOR... National Registration
More informationCHAPTER 53 PHARMACY AND POISONS ORDINANCE ARRANGEMENT OF SECTIONS PART I PRELIMINARY PART II PHARMACY
2 CAP. 53 Pharmacy and Poisons LAWS OF CHAPTER 53 PHARMACY AND POISONS ORDINANCE ARRANGEMENT OF SECTIONS PART I PRELIMINARY SECTION 1. Short title 2. Interpretation PART II PHARMACY 3. Qualification and
More informationPeople s Republic of China State Intellectual Property Office of China
[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Office: People s Republic of China
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
The answers to this questionnaire have been provided on behalf of: Country: Austria... Office: Austrian Patent Office (APO)... Person to be contacted: Name:... Title:... E-mail:... Telephone:... Facsimile:...
More informationPregabalin: Where stand plausibility, Swiss-form claims, late amendment and more?
University College London IBIL Innovation Seminar 2018 Pregabalin: Where stand plausibility, Swiss-form claims, late amendment and more? Dr. Matthias Zigann Presiding Judge Regional Court Munich I Swiss
More informationFINLAND Patents Act No. 550 of December 15, 1967 as last amended by Act No. 101/2013 of January 31, 2013 Enter into force on 1 September 2013
FINLAND Patents Act No. 550 of December 15, 1967 as last amended by Act No. 101/2013 of January 31, 2013 Enter into force on 1 September 2013 TABLE OF CONTENTS CHAPTER 1 General Provisions Section 1 Section
More informationPHARMACY AND DRUG ACT
Province of Alberta PHARMACY AND DRUG ACT Revised Statutes of Alberta 2000 Current as of January 1, 2017 Office Consolidation Published by Alberta Queen s Printer Alberta Queen s Printer 7 th Floor, Park
More informationpct2ep.com Guide to claim amendment after EPO regional phase entry
pct2ep.com Guide to claim amendment after EPO regional phase entry Claim amendments in the EPO Guide to the issues to consider After a PCT application enters the EPO regional phase, and before any search
More informationNew IP Code changes regarding patents, new post-grant opposition and enforcement provisions
INTELLECTUAL PROPERTY - TURKEY New IP Code changes regarding patents, new post-grant opposition and enforcement provisions AUTHORS Mehmet Nazim Aydin Deriş January 08 2018 Contributed by Deris Avukatlik
More informationPRESCRIPTION MONITORING PROGRAM MODEL ACT 2010 Revision
PRESCRIPTION MONITORING PROGRAM MODEL ACT 2010 Revision Section 1. Short Title. This Act shall be known and may be cited as the Prescription Monitoring Program Model Act. Section 2. Legislative Findings
More informationPart II. Time limit for completing the International search. Application not searched
II.6. Time limit for completing the International search Art.18(1) PCT The International search report must be ready within the prescribed time limit. R42.1 PCT The International search report (or the
More informationJordanian Patent Office
Jordanian Patent Office Industrial Property Protection Directorate Ministry of Industry and Trade UNDP/WHO - Examination of pharmaceutical patents from a public health perspective Cairo, 14-15 April 2009
More information2ND SESSION, 41ST LEGISLATURE, ONTARIO 66 ELIZABETH II, Bill 87. (Chapter 11 of the Statutes of Ontario, 2017)
2ND SESSION, 41ST LEGISLATURE, ONTARIO 66 ELIZABETH II, 2017 Bill 87 (Chapter 11 of the Statutes of Ontario, 2017) An Act to implement health measures and measures relating to seniors by enacting, amending
More informationSection 1: General. This question does not imply that the topic of exclusions from patentability is dealt with in this question exhaustively.
Section 1: General 1. As background for the exceptions and limitations to patents investigated in this questionnaire, what is the legal standard used to determine whether an invention is patentable? If
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
The answers to this questionnaire have been provided on behalf of: Country: Office: Republic of Poland Patent Office of the Republic of Poland Person to be contacted: Name: Piotr Czaplicki Title: Director,
More informationThe Consolidate Utility Models Act 1)
Consolidate Act No. 220 of 26 February 2017 The Consolidate Utility Models Act 1) Publication of the Utility Models Act, cf. Consolidate Act No. 190 of 1 March 2016 including the amendments which follow
More informationCase 2:14-cv HRH Document 37 Filed 12/08/14 Page 1 of 8
Case :-cv-00-hrh Document Filed /0/ Page of 0 0 ERICKSON KERNELL DERUSSEAU & KLEYPAS, LLC 00 State Line Road, Suite 00 Leawood, Kansas 0 Telephone: () -00 Facsimile: () - Email: jjk@kcpatentlaw.com kdd@kcpatentlaw.com
More information[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights
Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Chile... Office: National Institute of Industrial Property (INAPI)...
More information4. COMPARISON OF THE INDIAN PATENT LAW WITH THE PATENT LAWS IN U.S., EUROPE AND CHINA
4. COMPARISON OF THE INDIAN PATENT LAW WITH THE PATENT LAWS IN U.S., EUROPE AND CHINA Provisions of the Indian patent law were compared with the relevant provisions of the patent laws in U.S., Europe and
More information[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights
[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Office: Morocco... Moroccan Industrial
More informationREPUBLIC OF SOUTH AFRICA
Government Gazette REPUBLIC OF SOUTH AFRICA Vol. 451 Cape Town 17 January 2003 No. 24279 THE PRESIDENCY No. 115 17 January 2003 It is hereby notified that the President has assented to the following Act,
More informationBERMUDA PHARMACY AND POISONS ACT : 26
QUO FA T A F U E R N T BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS 1 2 3 4 4A 4B 5 6 7 7A 8 9 10 10A 10B 11 12 13 14 Short title Interpretation The Pharmacy Council Membership of
More informationLaw on the protection of inventions No. 50/2008 of the Republic of Moldova can be found at:
The answers to this questionnaire have been provided on behalf of: Country: Republic of Moldova... Office: The State Agency on Intellectual Property... Person to be contacted: Name: Cicinova Olga... Title:
More informationPsychotropic Substances Act B.E (1975) BHUMIBOL ADULYADEJ, REX. Given on 4th January B.E. 2518; Being the 30th year of the present Reign.
Psychotropic Substances Act B.E. 2518 (1975) BHUMIBOL ADULYADEJ, REX. Given on 4th January B.E. 2518; Being the 30th year of the present Reign. His Majesty King Bhumibol Adulyadej is graciously pleased
More information2017 Georgia New Pharmacy/Medical Legislative Activity. Revised,
2017 Georgia New Pharmacy/Medical Legislative Activity Revised, 2.12.2017 This document provides a summary of key points regarding each individual piece of legislation. Readers are to full current versions
More informationSWEDEN PATENTS ACT No.837 of 1967 in the version in force from July 1, 2014
SWEDEN PATENTS ACT No.837 of 1967 in the version in force from July 1, 2014 TABLE OF CONTENTS Chapter 1. General Provisions Article 1 Article 1a Article 1b Article 1c Article 1d Article 2 Article 3 Article
More informationREPUBLIC OF VANUATU BILL FOR THE PATENTS ACT NO. OF 1999
REPUBLIC OF VANUATU BILL FOR THE PATENTS ACT NO. OF 1999 Arrangement of Sections PART 1 PRELIMINARY PROVISIONS 1. Interpretation PART 2 PATENTABILITY 2. Patentable invention 3. Inventions not patentable
More informationPlausibility, 2nd medical use and late amendments - The Dutch perspective after UK SC 14 Nov 2018 pregabalin case
20 November 2018 Pregabalin UCL Pregabalin UCL Plausibility, 2nd medical use and late amendments - The Dutch perspective after UK SC 14 Nov 2018 pregabalin case Judge Edger F. Brinkman, senior judge, Court
More informationREGULATION (EU) No 649/2012 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 July 2012 concerning the export and import of hazardous chemicals
L 201/60 Official Journal of the European Union 27.7.2012 REGULATION (EU) No 649/2012 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 July 2012 concerning the export and import of hazardous chemicals
More informationREPUBLIC OF SINGAPORE GOVERNMENT GAZETTE ACTS SUPPLEMENT. Published by Authority NO. 28] FRIDAY, DECEMBER 21 [2012 REPUBLIC OF SINGAPORE
REPUBLIC OF SINGAPORE GOVERNMENT GAZETTE ACTS SUPPLEMENT Published by Authority NO. 28] FRIDAY, DECEMBER 21 [2012 First published in the Government Gazette, Electronic Edition, on 20th December 2012 at
More informationThe Pharmacy and Pharmacy Disciplines Act
The Pharmacy and Pharmacy Disciplines Act being Chapter P-9.1 of the Statutes of Saskatchewan, 1996 (effective January 1, 1998) as amended by the Statutes of Saskatchewan, 1998, c.6; 2002, c.r-8.2; 2003,
More informationWorking Guidelines Q217. The patentability criteria for inventive step / non-obviousness
Working Guidelines by Thierry CALAME, Reporter General Nicola DAGG and Sarah MATHESON, Deputy Reporters General John OSHA, Kazuhiko YOSHIDA and Sara ULFSDOTTER Assistants to the Reporter General Q217 The
More informationThe National Center of Intellectual Property Belarus. Contents
The National Center of Intellectual Property Belarus Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 3 Section 3: Experimental use and/or scientific research... 4 Section
More informationSAFE IMPORTATION OF MEDICAL PRODUCTS AND OTHER RX THERAPIES ACT OF 2004 (SAFE IMPORT ACT) SECTION-BY-SECTION SEC. 1. SHORT TITLE.
SAFE IMPORTATION OF MEDICAL PRODUCTS AND OTHER RX THERAPIES ACT OF 2004 (SAFE IMPORT ACT) SEC. 1. SHORT TITLE. SECTION-BY-SECTION Provides that the short title of the bill is the ASafe Importation of Medical
More informationThe Pharmacy and Pharmacy Disciplines Act
1 The Pharmacy and Pharmacy Disciplines Act being Chapter P-9.1 of the Statutes of Saskatchewan, 1996 (effective January 1, 1998) as amended by the Statutes of Saskatchewan, 1998, c.6; 2002, c.r-8.2; 2003,
More informationRevision Draft of the Patent Law of the People s Republic of China (For Deliberation)
Revision Draft of the Patent Law of the People s Republic of China (For Deliberation) (Words in bold font are revised portion) Chapter 1: General Provisions Article 1 This law is enacted for the purpose
More informationPHARMACY AND DRUG REGULATION
Province of Alberta PHARMACY AND DRUG ACT PHARMACY AND DRUG REGULATION Alberta Regulation 240/2006 With amendments up to and including Alberta Regulation 131/2018 Current as of June 28, 2018 Office Consolidation
More informationJOINT COMMITTEE ON AGENCY RULE REVIEW Agenda - 10/3/2011-1:30 P.M. Statehouse Hearing Room 121(William McKinley Room) Consent
Agenda - Consent 1 Department of Aging Total Rules: 1 Original Filing Date: 7/13/2011 Date of Refiled Filing: 9/9/2011 Jurisdiction Ends: 10/9/2011 Public Hearing: 9/15/2011 Amendment Refiled Filing Yes
More informationCOMPULSORY LICENCE in Germany. Markus Rieck LL.M.
COMPULSORY LICENCE in Germany Markus Rieck LL.M. 1 1877 - GERMAN PATENT ACT Bundesarchiv, Bild 183-R68588 / P. Loescher & Petsch / CC-BY-SA 3.0 2 Public interest Dependent patent Plant breeders privilege*
More informationDraft agreement on a Unified Patent Court and draft Statute - Revised Presidency text
COUNCIL OF THE EUROPEAN UNION Brussels, 26 October 2011 16023/11 PI 141 COUR 62 WORKING DOCUMENT from: Presidency to: Delegations No. prev. doc.: 15539/11 PI 133 COUR 59 Subject: Draft agreement on a Unified
More informationAmended proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EUROPEAN COMMISSION Brussels, 11.10.2011 COM(2011) 633 final 2008/0256 (COD) Amended proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL Amending Directive 2001/83/EC, as regards information
More informationSIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2018 BUDGET SESSION
AN ACT relating to controlled substances; creating an opioid addiction task force; specifying task force duties, membership and staffing; requiring coordination between the advisory council on palliative
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Australia... Office: IP Australia... Person to be contacted: Name:
More informationTitle: The patentability criterion of inventive step / non-obviousness
Question Q217 National Group: China Title: The patentability criterion of inventive step / non-obviousness Contributors: [Heather Lin, Gavin Jia, Shengguang Zhong, Richard Wang, Jonathan Miao, Wilson Zhang,
More informationHUNGARY Patent Act Act XXXIII of 1995 as consolidated on March 01, 2015
HUNGARY Patent Act Act XXXIII of 1995 as consolidated on March 01, 2015 TABLE OF CONTENTS PART I INVENTIONS AND PATENTS Chapter I SUBJECT MATTER OF PATENT PROTECTION Article 1 Patentable inventions Article
More informationFlorida Senate SB 518 By Senator Saunders
By Senator Saunders 1 A bill to be entitled 2 An act relating to controlled substances; 3 creating s. 831.311, F.S.; prohibiting the 4 sale, manufacture, alteration, delivery, 5 uttering, or possession
More informationIsrael. Contributing firm Pearl Cohen Zedek Latzer
Contributing firm Authors Nachman Cohen Zedek, Dor Cohen Zedek and Yossi Markovich Selection, clearance and registration Israel became party to the Madrid Protocol on September 1 2010. As of September
More informationTrade Marks Act, 1996 (Community Trade Mark) Regulations (S.I. No. 229 of 2000) The Irish Patent Office
Title Source Trade Marks Act, 1996 (Community Trade Mark) Regulations (S.I. No. 229 of 2000) The Irish Patent Office S.I. No. 229 of 2000. Trade Marks Act, 1996 (Community Trade Mark) Regulations, 2000
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
The answers to this questionnaire have been provided on behalf of: Country:... Office: Eurasian Patent Office (EAPO)... Person to be contacted: Name: CEBAN Aurelia... Title: Head, Section of Appeals and
More informationPHARMACEUTICAL AFFAIRS ACT
PHARMACEUTICAL AFFAIRS ACT Wholly Amended by Act No. 8365, Apr. 11, 2007 Wholly Amended by Act No. 8558, Jul. 27, 2007 Act No. 8643, Oct. 17, 2007 Act No. 8723, Dec. 21, 2007 Act No. 8728, Dec. 21, 2007
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
The answers to this questionnaire have been provided on behalf of: Country: Office: Bhutan Intellectual Property Division, Ministry of Economic Affairs, Thimphu Person to be contacted: Name: Mr. Sonam
More informationThe Pharmacy Act, 1996
1 The Pharmacy Act, 1996 being Chapter P-9.1 of the Statutes of Saskatchewan, 1996 (effective January 1, 1998) as amended by the Statutes of Saskatchewan, 1998, c.6; 2002, c.r-8.2; 2003, c.8; 2009, c.t-23.01;
More informationIC Chapter 19. Drugs: Indiana Legend Drug Act
IC 16-42-19 Chapter 19. Drugs: Indiana Legend Drug Act IC 16-42-19-1 Intent of chapter Sec. 1. This chapter is intended to supplement IC 16-42-1 through IC 16-42-4. IC 16-42-19-2 "Drug" Sec. 2. As used
More informationBRUNEI Patent Order 2011
BRUNEI Patent Order 2011 TABLE OF CONTENTS PART I PRELIMINARY 1. Citation, commencement and long title 2. Interpretation 3. Order to bind Government PART II ADMINISTRATION 4. Registrar of Patents and other
More information2016 Study Question (Patents)
2016 Study Question (Patents) Submission date: 25th May 2016 Sarah MATHESON, Reporter General John OSHA and Anne Marie VERSCHUUR, Deputy Reporters General Yusuke INUI, Ari LAAKKONEN and Ralph NACK, Assistants
More informationThe methods and procedures described must be directly applicable to production.
National Patent Administration Argentina Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 3 Section 3: Experimental use and/or scientific research... 3 Section 4: Preparation
More informationThe State Law and Order Restoration Council hereby enacts the following Law: Chapter I Title and Definition
The State Law and Order Restoration Council The National Drug Law (The State Law and Order Restoration Council Law No. 7/92) The 5th Waning Day of Tazaungmon, 1354 M.E. (30th October, 1992) The State Law
More informationCHAPTER 2 AUTHORS AND PATENT OWNERS Article 5. Author of the Invention, Utility Model, and Industrial Design Article 6.
BELARUS Law of the Republic of Belarus On Patents for Inventions, Utility Models, and Industrial Designs December 16, 2002 No 160-Z Amended as of December 22, 2011 TABLE OF CONTENTS CHAPTER 1. LEGAL PROTECTION
More informationThe Third Amendment to the Patent Law of China. On December 27, 2008, the Standing Committee of the National People's
The Third Amendment to the Patent Law of China On December 27, 2008, the Standing Committee of the National People's Congress adopted the third amendment to the Patent Law of the People's Republic of China,
More informationThe Myriad patent litigation Patentability of DNA molecules
The Myriad patent litigation Patentability of DNA molecules Presentation to the SIPO Delegation SIPO/US Bar Liaison Council with ACPAA Joint Symposium at Cardozo Law School New York City, June 3, 2013
More informationMATERIAL TRANSFER AGREEMENT UNIVERSITI SAINS MALAYSIA ABC
MATERIAL TRANSFER AGREEMENT BETWEEN UNIVERSITI SAINS MALAYSIA AND ABC MATERIAL TRANSFER AGREEMENT THIS MATERIAL TRANSFER AGREEMENT is made this... day of. 20 (hereinafter referred to as Agreement ); BETWEEN
More informationFederal Law on Medicinal Products and Medical Devices
Federal Law on Medicinal Products and Medical Devices (Law on Therapeutic Products LTP) dated 15 December 2000 (updated on 1 May 2007) The Federal Assembly of the Swiss Confederation, in accordance with
More information[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights
[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: HONDURAS... Office: DIRECTORATE GENERAL
More informationLiability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group: The Netherlands Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors: John Allen, Klaas Bisschop, Arnout Gieske, Willem
More informationCODING: Words stricken are deletions; words underlined are additions. hb e1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 A bill to be entitled An act relating to the Department of Business and Professional Regulation; amending s. 20.165, F.S.; creating
More information2010 No. 231 HEALTH CARE AND ASSOCIATED PROFESSIONS. The Pharmacy Order 2010
S T A T U T O R Y I N S T R U M E N T S 2010 No. 231 HEALTH CARE AND ASSOCIATED PROFESSIONS The Pharmacy Order 2010 Made - - - - 10th February 2010 Coming into force in accordance with article 1 1. Citation
More informationALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540 X 12 QUALIFIED ALABAMA CONTROLLED SUBSTANCES REGISTRATION CERTIFICATE (QACSC)
Medical Examiners Chapter 540 X 12 ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540 X 12 QUALIFIED ALABAMA CONTROLLED SUBSTANCES REGISTRATION CERTIFICATE (QACSC) TABLE OF CONTENTS 540
More informationGENEVA STANDING COMMITTEE ON THE LAW OF PATENTS. Thirteenth Session Geneva, March 23 to 27, 2009
E WIPO SCP/13/3. ORIGINAL: English DATE: February 4, 2009 WORLD INTELLECTUAL PROPERT Y O RGANI ZATION GENEVA STANDING COMMITTEE ON THE LAW OF PATENTS Thirteenth Session Geneva, March 23 to 27, 2009 EXCLUSIONS
More informationLaw on Inventive Activity*
Law on Inventive Activity* (of October 19, 1972, as amended by the Law of April 16, 1993) TABLE OF CONTENTS** Article Part I: General Provisions... 1 9 Part II: Inventions and Patents 1. Patents... 10
More informationSupreme Court of the Netherlands. in the matter of:
Pharma and Pharmachemie; English translation of IEF 17241; www.ie-forum.nl/?showarticle=17241 ) 3 November 2017 First Chamber 15/04934 RM/EE Supreme Court of the Netherlands Judgment in the matter of:
More informationMEDICINES AND RELATED SUBSTANCES AMENDMENT BILL
REPUBLIC OF SOUTH AFRICA MEDICINES AND RELATED SUBSTANCES AMENDMENT BILL (As introduced in the National Assembly (proposed section 7); explanatory summary of Bill published in Government Gazette No. 31114
More information(Translated by the Patent Office of the People's Republic of China. In case of discrepancy, the original version in Chinese shall prevail.
Patent Law of the People's Republic of China (Adopted at the 4th Session of the Standing Committee of the Sixth National People's Congress on March 12, 1984, Amended by the Decision Regarding the Revision
More informationEquality Impact Assessment. Section One: General Information: McKenzie HR Consultants in consultation with the General Pharmaceutical Council
Section One: General Information: 1.1 Name of person completing this assessment: McKenzie HR Consultants in consultation with the General Pharmaceutical Council Function: Corporate Governance (Equality
More informationYoung EPLAW Congress. Bolar provision: a European tour. Brussels, 27 April 2015 Guillaume Bensussan Kathy Osgerby Agathe Michel de Cazotte
Young EPLAW Congress Bolar provision: a European tour Brussels, 27 April 2015 Guillaume Bensussan Kathy Osgerby Agathe Michel de Cazotte Introduction Bolar provision: a European tour Part 1 UK A) Recent
More informationUniversity of South Florida Pre-Approved Material Transfer Agreement Based upon the UBMTA
University of South Florida Pre-Approved Material Transfer Agreement Based upon the UBMTA This Agreement effective this day of, 20, is between The University of South Florida Board of Trustees, a public
More informationEnglish Language Translation Entry into New Zealand PCT National Phase
2009 Business Updates Request for postponement of acceptance under section 20(1) of the Patents Act 1953 Applicants may at any time prior to acceptance request that a patent application not be accepted
More informationHOUSE AMENDMENT Bill No. HB 5511 (2012) Amendment No. CHAMBER ACTION
CHAMBER ACTION Senate House. 1 The Conference Committee on HB 5511 offered the following: 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Conference Committee Amendment (with title amendment) Remove everything after
More informationCHAPTER House Bill No. 5511
CHAPTER 2012-143 House Bill No. 5511 An act relating to the Department of Business and Professional Regulation; amending s. 20.165, F.S.; creating the Division of Drugs, Devices, and Cosmetics within the
More informationPatent Law of the Republic of Kazakhstan. Chapter 1. General provisions. Article 1. Basic notions and definitions used in the present Law
Patent Law of the Republic of Kazakhstan Chapter 1. General provisions Article 1. Basic notions and definitions used in the present Law The following notions and definitions are used for the purposes of
More information